Efficacy of DMP 840: A Novel Bis-Naphthalimide Cytotoxic Agent with Human Solid Tumor Xenograft Selectivity

Cancer Research

Volumn 54, Issue 1, 1994, Pages 159-164

  McRipley, R J ^a   Burns Horwitz, P E ^a   Czerniak, P M ^a   Diamond, R J ^a   Diamond, M A ^a   Miller, J L D ^a   Page, R J ^a   Dexter, D L ^c   Chen, S F ^d   Sun, J H ^b   Behrens, C H ^b   Seitz, S P ^b  

^a Molecular Biology Division   (United States)

^b DUPONT COMPANY   (United States)

^c Institute for Drug Development ^*  (United States)

^d CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2' [1,2 ETHANEDIYLBIS[IMINO(1 METHYL 2,1 ETHANEDIYL)]]BIS(5 NITRO 1H BENZ[DE]ISOQUINOLINE 1,3(2H) DIONE)DIMETHANESULFONIC ACID; BISNAFIDE MESYLATE; CYTOTOXIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MELANOMA; MOUSE; MURINE LEUKEMIA; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN; ISOQUINOLINES; LEUKEMIA L1210; LEUKEMIA P388; LUNG NEOPLASMS; MALE; MESYLATES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0028123489     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chen, S-F., Behrens, D. L. Behrens, C. H. Czerniak, P. M. Dexter, D. L. Dusak, B. Fredericks, J. R. Gale, K. C. Gross, J. L. Jiang, J. B. Kirshenbaum, M. R. McRipley, R. J. Papp, L. M. Patten, A. D. Perrella, F. W. Seitz, S. P. Stafford, M. P. Sun, J-H. Sun, T., and Von Hoff, D. D. XB596: a promising bis-naphthalimide anti-cancer agent. Anti-Cancer Drugs, 4: 447–457, 1993.
2. Sun, J-H. Behrens, C. H. Chen, S-R., Kirshenbaum, M. McRipley, R. J., and Gross, J. L. Synthesis and anti-proliferative properties of novel bis-naphthalimides, of DMP 840 and its stereoisomers. Proc. Am. Assoc. Cancer Res. 34: 384, 1993.
3. Papp, L. M. Kirshenbaum, M. R. Chen, S-F., Stafford, M. M. Fredericks, J. R. Behrens, D. L. Behrens, C. H. Sun, J. H., and Gross, J. L. Mechanistic and antiproliferative activities of DMP 840, a novel bis-naphthalimide anti-tumor agent. Proc. Am. Assoc. Cancer Res. 34: 384, 1993.
4. Stafford, M. M. Kirshenbaum, M. R. Elliott, K. J. Chen, S-F., Perrella, R. Sun, T. Trainor, G. L. Papp, L. M. Fredericks, J. R. Sun, J. H., and Gross, J. L. DNA binding characteristics of DMP 840, a novel bis-naphthalimide tumor agent. Proc. Am. Assoc. Cancer Res. 34: 384, 1993.
5. Houghton, P. J. Cheshire, P. J. Hallman, J. Sun, J-H. Behrens, C. H. McRipley, R., and Gross, J. L. Evaluation of DMP 840, a novel anti-tumor agent in xenografts derived from adult and childhood malignancies. Proc. Am. Assoc. Cancer Res. 34: 368, 1993.
6. Goldin, A. Venditti, J. M. MacDonald, J. S. Muggia, R M. Henney, J. E., and DeVita, J. T. Jr. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur. J. Cancer, 17: 129–142, 1981.
7. Dexter, D. L. Spremullli, E. N. Matook, G. M. Diamond, I., and Calabresi, P. Inhibition of the growth of human colon cancer xenografts by polar solvents. Cancer Res. 42: 5018–5022, 1982.
8. Geran, R. I. Greenberg, N. H. MacDonald, M. M. Schumaker, A. M., and Abbot, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. 3: 1–103, 1972.
9. Dexter, D. L. Hesson, D. P. Ardecky, R. J. Rao, G. V. Tippett, D. L. Dusak, B. A. Paull, K. D. Plowman, J. DeLarco, B. M. Narayanan, V. L., and Forbes, M. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2′-fluoro-l, r-bi-phenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt], against experimental tumors. Cancer Res. 45: 5563–5568, 1985.
10. LoRusso, P. M. Demchik, L. Polin, L. Jones, J. Knight, J. Behrens, C. H. Sun, J. H. McRipley R. J. Gross, J. L. Corbett, T. H. Antitumor activity of DMP 840. Proc. Am. Assoc. Cancer Res. 34: 380, 1993.
11. Jackson, R. C. Sebolt, J. S. Shillis, J. L., and Leopold, W. R. The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest. 8: 39–47, 1990.
12. Staquet, M. J. Byar, D. P. Green, S. B., and Rozencweig, M. Clinical predictability of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three stage strategy. Cancer Treat. Rep. 67: 753–765, 1983.
13. Giovanella, B. C. Stehlin, J. S. Wall, M. E. Wani, M. C. Nicholas, A. W. Liu, L. F. Silber, R., and Potmesil, M. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046–1048, 1989.
14. Li, L. H. Kelly, R. C. Warpehoski, M. A. McGovern, J. P. Gebhard, I., and DeKoning, T. F. Adozelesin, a selected lead among cyclopropylpyrroloindole analogs of the DNA-binding antibiotic, CC-1065. Invest. New Drugs, 9: 137–148, 1991.
15. Li, L. H. DeKoning, T. F. Kelly, R. C. Krueger, W. C. McGovern, J. P. Padbury, G. E. Petzold, G. L. Wallace, T L. Ouding, R. J. Prairie, M. D., and Gebhard, I. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res. 52: 4904–4913, 1992.
16. Pierre, A, Kraus-Berthier, L. Atassi, G. Cros, S. Poupon, M-F., Lavielle, G. Berlion, M., and Bazzari, J-P. Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363. Cancer Res. 51: 2312–2318, 1991.
17. Grindey, G. B. Current status of cancer drug development: failure or limited success? Cancer Cells (Cold Spring Harbor), 2: 163–171, 1990.
18. Mattern, J. Bak, M. Hahn, E. W., and Volm, M. Human tumor xenografts as models for drug testing. Cancer Metastasis Rev. 7: 263–284, 1988.
19. Rose, W. C. Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs, 3: 311–321, 1992.
20. Leopold, W. R. Nelson, J. M. Plowman, J., and Jackson, R. C. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res. 45: 5532–5539, 1985.